Deferiprone

Catalog No.S4067 Batch:S406704

Print

Technical Data

Formula

C7H9NO2
Molecular Weight 139.15 CAS No. 30652-11-0
Solubility (25°C)* In vitro Water 14 mg/mL (100.61 mM)
DMSO Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Deferiprone (CP20) is a chelating agent with an affinity for ferric ion (iron III)，binds with ferric ions to form neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values.
In vitro Deferiprone (100 μM) is able to protect myocytes from doxorubicin-induced lactate dehydrogenase release. Deferiprone (300 μM) quickly and efficiently removes iron(III) from its complex with doxorubicin. Deferiprone (300 μM) rapidly enters myocytes and displaces iron from a fluorescence-quenched trapped intracellular iron-calcein complex, suggesting that in the myocyte, deferiprone should also be able to displace iron from its complex with doxorubicin. Deferiprone (3 mM) also greatly reduces hydroxyl radical production by the iron(III)-doxorubicin complex in the xanthine oxidase/xanthine superoxide generating system. [1] Deferiprone (0.5 mM) increases removal of RBC membrane free iron in a time and dose dependent manner. [2] Deferiprone (0.3 mM) is effective in inhibiting radioactive iron mobilization from iron-loaded heart cells and protecting or restoring mitochondrial respiratory enzyme activity. Deferiprone (1 mM) results in a sharp decrease in complex I-III activity in iron-loaded heart cells. [3] Deferiprone shows cytotoxic effect of human tumor cell lines HSC-2, HSC-3 and HL-60 with IC50 of 13.5 μg/mL, 9.9 μg/mL and 10.6 μg/mL, the cytotoxic activity of HK1 against HL-60 and HSC-2 cells is reduced in the presence of FeCl3. Deferiprone (100 μg/mL) induces internucleosomal DNA fragmentation in HL-60 cells, but the addition of FeCl3 inhibits the DNA fragmentation. Deferiprone (100 μg/mL) activates the caspase 3, 8 and 9 in HSC-2 cells. [4]
In vivo Deferiprone (100 mg/kg) reduces the mean basilar artery cross-sectional areas by 24% in rabbits. Deferiprone (100 mg/kg) combined with subarachnoid hemorrhage(SAH) shows a variable amount of corrugation of the internal elastic lamina in rabbits. [5]
Features Possesses 10-fold higher cytotoxicity than maltol in both HL-60 and HSC-2 cell lines.

Protocol (from reference)

Selleck's Deferiprone has been cited by 14 publications

Irradiated tumour cell-derived microparticles upregulate MHC-I expression in cancer cells via DNA double-strand break repair pathway [ Cancer Lett, 2024, 592:216898] PubMed: 38670306
Sevoflurane Exposure Induces Neuronal Cell Ferroptosis Initiated by Increase of Intracellular Hydrogen Peroxide in the Developing Brain via ER Stress ATF3 Activation [ Mol Neurobiol, 2024, 61(4):2313-2335] PubMed: 37874483
Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer [ Cell Death Dis, 2023, 14(8):532] PubMed: 37596261
Selective ablation of primary and paracrine senescent cells by targeting iron dyshomeostasis [ Cell Rep, 2023, 42(2):112058] PubMed: 36753419
The Effect of 4-Methylcatechol on Platelets in Familial Hypercholesterolemic Patients Treated with Lipid Apheresis and/or Proprotein Convertase Subtilisin Kexin 9 Monoclonal Antibodies [ Nutrients, 2023, 15(8)1842] PubMed: 37111061
Effects of Supplemental Drugs on Hexaminolevulinate (HAL)-Induced PpIX Fluorescence in Bladder Cancer Cell Suspensions [ Int J Mol Sci, 2022, 23(14)7631] PubMed: 35886979
Iron contributes to photoreceptor degeneration and Müller glia proliferation in the zebrafish light-treated retina [ Exp Eye Res, 2022, 216:108947] PubMed: 35074344
Shuganning injection, a traditional Chinese patent medicine, induces ferroptosis and suppresses tumor growth in triple-negative breast cancer cells [ Phytomedicine, 2021, 85:153551] PubMed: 33827043
Berberine alleviates liver fibrosis through inducing ferrous redox to activate ROS-mediated hepatic stellate cells ferroptosis [ Cell Death Discov, 2021, 7(1):374] PubMed: 34864819
Iron chelators inhibit amyloid-β-induced production of lipocalin 2 in cultured astrocytes. [ Neurochem Int, 2020, 132:104607] PubMed: 31760034

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.